Professor Barry Furr, a non-executive director at the animal breeding technology group Genus, has spent £30,000 more than doubling his stake in the animal breeding company, the firm confirmed today.
He bought 5,000 shares at 600p a time and now has 8,000.
Furr, a former chief scientist for the drug giant AstraZeneca, bought his initial stake of 3,000 shares at 680p a time in October.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Genus sells breeding technology products to livestock and farmers.
Top Director Buys
Value: £61,350
Value: £30,000
Value: £24,880
Value: £14,880
Top Director Sells
Value: £410,000
-
Saba Capital and Boaz Weinstein respond to investment trustsAs investment trust managers and industry experts accuse Saba of self-motivated opportunism, the hedge fund responds to specific "misleading claims" and sets out its stall
-
How to find top-quality companies with growing dividendsIan Mortimer, portfolio manager of Guinness Global Equity Income Fund, shares where he would put his money for sustainable and growing dividends
